These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35394563)

  • 1. Development and consensus process for a clinical pathway for the assessment and management of chemotherapy-induced peripheral neuropathy.
    Mizrahi D; Goldstein D; Kiernan MC; Robinson L; Pitiyarachchi O; McCullough S; Mendoza-Jones P; Grimison P; Boyle F; Park SB
    Support Care Cancer; 2022 Jul; 30(7):5965-5974. PubMed ID: 35394563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of the consensus-based recommendations for Podiatry care of Neuropathy In Cancer Survivors (PodNICS): a Delphi consensus study of Australian podiatrists.
    Dars S; Buckley E; Beckmann K; Roder D; Banwell H
    J Foot Ankle Res; 2023 Jun; 16(1):33. PubMed ID: 37291602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey.
    McCrary JM; Goldstein D; Boyle F; Cox K; Grimison P; Kiernan MC; Krishnan AV; Lewis CR; Webber K; Baron-Hay S; Horvath L; Park SB;
    Support Care Cancer; 2017 Nov; 25(11):3485-3493. PubMed ID: 28589310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy.
    Knoerl R; Weller E; Halpenny B; Berry D
    BMC Cancer; 2018 Dec; 18(1):1203. PubMed ID: 30514351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.
    Molassiotis A; Cheng HL; Leung KT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; Ng TR; Suen LKP; Chan CW; Yorke J; Lopez V
    Brain Behav; 2019 Jun; 9(6):e01312. PubMed ID: 31063261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chinese expert consensus on the diagnosis and treatment of chemotherapy-induced peripheral neuropathy (2022 edition)].
    ;
    Zhonghua Zhong Liu Za Zhi; 2022 Sep; 44(9):928-934. PubMed ID: 36164693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying trajectories and predictors of chemotherapy-induced peripheral neuropathy symptoms, physical functioning, and falls across treatment and recovery in adults treated with neurotoxic chemotherapy: the PATTERN observational study protocol (NCT05790538).
    Winters-Stone KM; Krasnow SM; Horak FB; Mancini M; Cameron MH; Dieckmann NF; Stoyles SA; Roeland EJ
    BMC Cancer; 2023 Nov; 23(1):1087. PubMed ID: 37946117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the impact of a decision support algorithm to improve clinicians' chemotherapy-induced peripheral neuropathy assessment and management practices: a two-phase, longitudinal study.
    Knoerl R; Mazzola E; Hong F; Salehi E; McCleary N; Ligibel J; Reyes K; Berry DL
    BMC Cancer; 2021 Mar; 21(1):236. PubMed ID: 33676431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Framework to leverage physical therapists for the assessment and treatment of chemotherapy-induced peripheral neurotoxicity (CIPN).
    Stoller S; Capozza S; Alberti P; Lustberg M; Kleckner IR
    Support Care Cancer; 2023 Apr; 31(5):293. PubMed ID: 37086308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of the FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric high risk Hodgkin lymphoma: report from the Children's Oncology Group AHOD 1331 study.
    Parsons SK; Rodday AM; Pei Q; Keller FG; Wu Y; Henderson TO; Cella D; Kelly KM; Castellino SM
    J Patient Rep Outcomes; 2023 Nov; 7(1):113. PubMed ID: 37947987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy.
    McCrary JM; Goldstein D; Trinh T; Timmins HC; Li T; Friedlander M; Bosco A; Harrison M; Maier N; O'Neill S; Park SB
    J Pain Symptom Manage; 2019 Dec; 58(6):1023-1032. PubMed ID: 31374367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade.
    Tan AC; McCrary JM; Park SB; Trinh T; Goldstein D
    Support Care Cancer; 2019 Dec; 27(12):4771-4777. PubMed ID: 30972648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention, diagnosis and management of chemotherapy-induced peripheral neuropathy: a cross-sectional study of French oncologists' professional practices.
    Selvy M; Pereira B; Kerckhove N; Busserolles J; Farsi F; Guastella V; Merle P; Pezet D; Balayssac D
    Support Care Cancer; 2021 Jul; 29(7):4033-4043. PubMed ID: 33403401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data.
    Gewandter JS; Kleckner AS; Marshall JH; Brown JS; Curtis LH; Bautista J; Dworkin RH; Kleckner IR; Kolb N; Mohile SG; Mustian KM
    Support Care Cancer; 2020 Jun; 28(6):2553-2562. PubMed ID: 31494735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical assessment of chemotherapy-induced peripheral neuropathy: a discrete choice experiment of patient preferences.
    Yu A; Street D; Viney R; Goodall S; Pearce A; Haywood P; Haas M; Battaglini E; Goldstein D; Timmins H; Park SB
    Support Care Cancer; 2021 Nov; 29(11):6379-6387. PubMed ID: 33884508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy-Induced Peripheral Neuropathy Detection via a Smartphone App: Cross-sectional Pilot Study.
    Chen CS; Kim J; Garg N; Guntupalli H; Jagsi R; Griggs JJ; Sabel M; Dorsch MP; Callaghan BC; Hertz DL
    JMIR Mhealth Uhealth; 2021 Jul; 9(7):e27502. PubMed ID: 36260403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterizing patient-clinician chemotherapy-induced peripheral neuropathy assessment and management communication approaches.
    Knoerl R; Smith EML; Han A; Doe A; Scott K; Berry DL
    Patient Educ Couns; 2019 Sep; 102(9):1636-1643. PubMed ID: 31003878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of the comprehensive assessment scale for chemotherapy-induced peripheral neuropathy in survivors of cancer.
    Kanda K; Fujimoto K; Mochizuki R; Ishida K; Lee B
    BMC Cancer; 2019 Sep; 19(1):904. PubMed ID: 31506070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examining the Impact of a Web-Based Intervention to Promote Patient Activation in Chemotherapy-Induced Peripheral Neuropathy Assessment and Management.
    Knoerl R; Lee D; Yang J; Bridges C; Kanzawa-Lee G; Lita Smith G; Lavoie Smith EM
    J Cancer Educ; 2018 Oct; 33(5):1027-1035. PubMed ID: 28265863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Living with chemotherapy-induced peripheral neuropathy: Uncovering the symptom experience and self-management of neuropathic symptoms among cancer survivors.
    Chan CW; Cheng H; Au SK; Leung KT; Li YC; Wong KH; Molassiotis A
    Eur J Oncol Nurs; 2018 Oct; 36():135-141. PubMed ID: 30322504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.